AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. Piper ...

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns and defensive upside.

The Food and Drug Administration has approved an updated label for Amyvid (florbetapir F 18 injection) to support Alzheimer disease diagnosis in patients.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

The FDA has approved required updates to the labeling of Pfizer’s Comirnaty and Moderna’s Spikevax COVID-19 vaccines to include revised warnings about the risk of myocarditis and pericarditis ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.

Get the latest stock analysis from Benzinga? This article FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection originally appeared on Benzinga.com ...

Camzyos (mavacamten) is a prescription capsule that treats obstructive hypertrophic cardiomyopathy in adults. Learn about price, side effects, and more.

FDA lowers echo monitoring to every 6 months for select Camzyos patients in maintenance phase. Camzyos label update removes prior contraindications with certain CYP inhibitors. Get the Strategy to ...

Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, simplifying treatment for patients and physicians by ...